News
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....
CVS Health Hopes Partnerships Will Power Growth
CVS Health Corp (NYSE: CVS) has had a rough go of it during the past year. Over the last twelve months, shares in the pharmaceutical drug store chain and pharmacy benefit manager (PBM) have dipped....
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE: PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly type of leukemia. The approval....
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now
Forty years is a long time. But it's not an unimaginably long time. For many Americans, 40 years is roughly the length of time they will spend or have spent in the workforce.Those years will end....
3 Top Biotech Stocks Under $5
The biotech field is littered with stocks under $5 that probably won't walk away from the crash landings that made them look so cheap. You'll be glad to know that sifting through the wreckage to....
These Stocks Have Tripled This Year
The stock market has made a lot of people rich since 2009, as several major benchmarks have tripled or even quadrupled during the past eight years. Yet for individual stocks, gains can come a lot....
3 Healthcare Stocks I'll Hold Forever
Fund managers who need to look busy might hate to admit it, but doing nothing is usually the best course of action for most investors. That doesn't mean it's a good idea to look the other way when....
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE: JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet Johnson & Johnson has
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a staple in the portfolios of conservative long-term investors and seniors alike.For decades, J&J, as the company is more commonly known, has
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very